InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (January 2026)
25 slides from InMed Pharmaceuticals's investor presentation, January 2026
Slide 1: Corporate Presentation
Corporate Presentation January 2026 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Pipeline of Proprietary Small Molecule Drug Candidates
Pipeline of Proprietary Small Molecule Drug Candidates TARGETING CB1/CB2 RECEPTORS • Robust R&D pipeline with 3 pharma candidates: - Alzheimer’s – Reduces inflammation, multi-factorial approach - Ocular – Functional and pathological improvements for dry AMD - Dermatology - Phase 2 completed in EB, c
Slide 4: A Uniquely Positioned Pharmaceutical Company
A Uniquely Positioned Pharmaceutical Company Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical programs candidates biosynthesis expertise and wellness industry • Skin, ocular and • Cannabinoid an
Slide 5: Drug Development Programs
Drug Development Programs
Slide 6: Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2
Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2 HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 • In vivo studies – reduced neuroinflammation, improved neuronal function, neuroprotection, INM-901 Improvement in cognitive function, memory, locomotor and anxiety-based behavior Alzheimer’s d
Slide 7: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • 7.2M Americans affected the part of the brain that controls thought, memory • 1 in 9 people age 65+ (11%) an
Slide 8: A New Perspective on Inflammation Response in Alzheimer's Disease
A New Perspective on Inflammation Response in Alzheimer’s Disease OLD VIEW NEW VIEW Aβ & Tau Aβ & Tau Vicious Neuronal Damage Cycle Neuronal Damage Neuroinflammation Inflammation (Cleanup Response)
Slide 9: INM-901: May Address Multiple Alzheimer's Pathologies
INM-901: May Address Multiple Alzheimer’s Pathologies AD INM-901 Ca2+ influx INOS FAAH GFAP TNF-⍺ IL-1β IL-6 CB2 COX-2
Slide 10: Limitations of Anti-Amyloid Beta Targeting Monoclonal Antibodies
Limitations of Anti-Amyloid Beta Recently approved Alzheimer’s disease Targeting Monoclonal Antibodies treatments aim to reduce the accumulation of amyloid-beta plaques Aβ Antibody Profile INM-901 Target Profile* and may slow the rate of cognitive decline, but none have been shown to Limited Limited
Slide 11: Well-characterized Study Design Using 5xFAD Mouse Model
Well-characterized Study Design Using 5xFAD Mouse Model LONGER TREATMENT DURATION AND ADVANCED DISEASE STAGE + + + 9 months old male mice at study conclusion 2-month-old male mice were injected twice-weekly for 7 months After seeing positive results in short term studies we conducted this long-term
Slide 12: INM-901: Summary of Data-to-Date
INM-901: Summary of Data-to-Date Anti-Inflammatory Action – 5xFAD Neuroprotection Robust Bioavailability Significantly reduced Significantly reduced amyloid-beta-induced cell Oral formulation achieved inflammatory biomarkers IFN-γ, death in in vitro studies anticipated therapeutic levels TNF-α, IL-1
Slide 13: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans aged 40+ central vision, eventually leading to loss • 12.6% of the U.S. population of vision. It happens when aging causes
Slide 14: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 15: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD Ability to proactively A preferential signaling ligand protect the retinal for CB1 and CB2 ganglion cells Demonstrated promise in preserving retinal Improved the thickness of function in an INM-089 the outer nuclear layer of the retina where the
Slide 16: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 17: Pipeline Next Steps
Pipeline Next Steps Research & Development INM-901 • Continuing CMC activities for drug substance and drug product • Pre-IND meeting prior to GLP Studies • GLP studies to follow INM-089 • Advancing towards Pre-IND meeting • GLP studies to follow Business Development - For all 3 programs • Identify c
Slide 18: BayMedica Commercial Business
BayMedica Commercial Business
Slide 19: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C OST- E F FE C T IV E NES S High quality, bioidentical rare cannabinoids with exceptional Mult
Slide 20: BayMedica Financial Performance
BayMedica Financial Performance Calendar Year Revenue Growth US$ (Fiscal year ends June 30) (000’s) 1,400 • Trailing 12-month revenue is $4.9M 1,200 • Volumes of Kgs sold have more than doubled 1,000 over the last 18 months 800 • Currently operating as a cash flow positive 600 business 400 200 0 4Q2
Slide 21: Corporate
Corporate
Slide 22: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT Eric A. Adams, MIBS Neeta Jagpal, CPA Michael Woudenberg, PEng Colin Clancy Shane Johnson, MD Chief Executive Officer Chief Financial Officer Chief Operating Officer VP, IR & Corp Comms SVP & GM, BayMedica 30+ years of
Slide 23: Financial Snapshot (As of 01/16/2026)
Financial Snapshot ( As of 01/16/2026) Cash and Short-term Investments $9.3M(1) Shares I/O 4.2 M(2) Options 62 K Warrants and Preferred Investment Options 2.4 M Fully Diluted Shares 6.7 M Close $1.10 52-week High $8.27 52-week Low $1.03 Average Daily Volume (Trailing 50 Days) 417 K Market Cap $4.7 M
Slide 24: 2026 – Key Value Drivers
2026 – Key Value Drivers • Advance INM-901 in ALZ towards IND filing / subsequent human clinical trials • Develop INM-089 in Dry AMD towards IND filing / subsequent human clinical trials • Target additional proprietary drug candidates for pharma R&D pipeline • Identify and execute on strategic initi
Slide 25: Thank you!
Thank you! Forward Inquiries to, Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (January 2026) on 6ix